This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
Clinical Hematology International Open Access 03 January 2023
-
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Annals of Hematology Open Access 16 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(12):1713–18.
Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454–9.
Soiffer R, Chen Y. Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. Blood Adv. 2017;1(25):2473–82.
Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemo resistance in acute myeloid leukemia: its correlation with FLT3. PubMed PMID: 23906301. Neoplasma . 2013;60(6):666–75.
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17.
Pollyea DA, Dinardo CD, Thirman MJ, Letai A, Wei AH, Jonas BA. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy. J Clin Oncol. 2016;34(15_suppl):7009.
Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, et al. Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors. Biol Blood Marrow Transplant. 2018;24(5):1013–21.
Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA et al. Management of venetoclax - posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;359–367.
Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26(11):2353–59.
Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101(7):879–83.
Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785–90.
Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Adoptive cellular therapy with donor lymphocyte infusion versus a second allogeneic hematopoietic cell transplant for post-allograft relapsed acute myeloid leukemia: an intent-to-treat analysis on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood. 2017;130(suppl 1):273.
DiNardo CD, Pollyea DA, Jonas BA, Konopleva M, Pullarkat V, Wei A, et al. Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment naive, elderly patients with acute myeloid leukemia. Blood . 2017;130(Suppl 1):2628.
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–07.
Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM. et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018. https://doi.org/10.3324/haematol.2018.188094.
Liu B, Narurkar R, Hanmantgad M, Zafar W, Song Y, Liu D, et al. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report. Front Med. 2018. https://doi.org/10.1007/s11684-018-0635-y
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Moukalled, N.M., El Darsa, H., Haibe, Y. et al. Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation. Bone Marrow Transplant 54, 620–624 (2019). https://doi.org/10.1038/s41409-018-0347-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0347-6
This article is cited by
-
Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
Clinical Hematology International (2023)
-
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Annals of Hematology (2021)
-
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
Annals of Hematology (2019)
-
Antineoplastics
Reactions Weekly (2019)